Analystreport

Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is now covered by analysts at Goldman Sachs Group Inc. They set a "hold" rating and a $256.00 price target on the stock.

Ligand Pharmaceuticals Incorporated  (LGND) 
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.ligand.com